Print Page | Contact Us | Report Abuse | Sign In | Register
Webinar: Oral Naltrexone: Not a Primary Medication Assisted Treatment – But Still Worth Knowing
Tell a Friend About This EventTell a Friend

This webinar will review current studies and practices around the use of Oral naltrexone (NTX-PO), a potent blocker at brain opioid receptors, which has been utilized in addition treatment.

When: Wednesday, 03/21/2018
10:00 AM - 12:00 PM
Where: United States
Presenter: David R. Gastfriend, MD, DFASAM
Contact: Lee Ann Griffin
(850) 878-2196

« Go to Upcoming Event List  


Oral naltrexone (NTX-PO) is a potent blocker at brain opioid receptors, so it was a natural consideration as a medication in addiction treatment (MAT) for Opioid Use Disorder (OUD). For most OUD patients, however, studies have not found NTX-PO to be any better than placebo or non-medication treatment – due to poor adherence by patients. Nevertheless, it is still used for patients whose pill-taking can be regularly monitored, for detoxification and induction onto extended-release naltrexone, and for patients who have completed MAT but encounter new stressors for which they may want temporary protection from relapse.

Who should attend?
This training is relevant to a variety of health and human service professionals and paraprofessionals, such as health care professionals (physicians, pharmacists, nurses, emergency medical personnel, etc.), law enforcement, mental health and addiction professionals, behavioral health technicians, recovery support personnel, and community members at risk of experiencing or witnessing an opioid overdose.

Presented by:
Dr. Gastfriend is a Senior Research Scientist at the Treatment Research Institute (TRI). An addiction psychiatrist, he directed addiction research at Massachusetts General Hospital and was an investigator in the NIDA Cocaine Collaborative Study, the NIAAA COMBINE Study and the NIDA Clinical Trials Network. As Vice President at Alkermes, Inc., Dr. Gastfriend conducted biological, clinical, health economics and policy research on behalf of the company’s efforts in the field of addiction treatment. For 25 years, Dr. Gastfriend served on the faculty of Harvard Medical School, notably as the Director of the Addiction Research Program at Massachusetts General Hospital and founder of the MGH/McLean Hospital Fellowship in Addiction Psychiatry. He is considered the world’s leading expert on two important treatment tools from both the biological and psychosocial realms: the opioid blocker Vivitrol, and the American Society of Addiction Medicine (ASAM) Criteria Software.  Dr. Gastfriend’s ASAM Criteria research contributed to their endorsement by most U.S. states, the VA and DOD. His 150 scientific publications include The ASAM Criteria and Addiction Treatment Matching. His CONTINUUM – The ASAM Criteria Decision Engine™ and ASAM’s CO-Triage™ are being used across Los Angeles County, the California state prison system, Massachusetts, and elsewhere. Dr. Gastfriend’s newest project is DynamiCare Health™, a technology platform for scaling up Contingency Management treatment and machine learning predictive analytics for routine care. He has consulted to the governments of Belgium, China, Iceland, Israel, Norway, Russia and the U.S. He received his B.A. at Haverford College in Philadelphia, and his M.D. from Jefferson Medical College in Philadelphia.

2 Continuing Education Units/Contact Hours are provided for this event
Florida Certification Board Approved Education Provider, #001-A
Florida Board of Social Work, Marriage and Family Therapy and Mental Health Counseling Provider #50-676
Florida Board of Nursing Provider #50-676